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Summary 
We have found that four taxanes with chemical modifications at positions C10 
and C13 were active against all types of taxane resistant cell lines, resistant by p-Gp 
overexpression, by mutations in the β-tubulin binding site or by overexpression of the 
highly dynamic βΙΙΙ-tubulin isotype.  
We have characterized the interaction of taxanes with high activity on 
chemotherapy resistant tumoural cells with microtubules, and also studied their cellular 
effects. The biochemical property enhanced in comparison with other taxanes is their 
potency at inducing tubulin assembly, despite the fact that their interactions with the 
microtubule binding sites (pore and luminal) are similar as studied by NMR and SAXS. 
A differential interaction with the S7-S9 loop (M-loop) is responsible for their enhanced 
assembly induction properties. The chemical changes in the structure also induce 
changes in the thermodynamic properties of the interaction, indicating a higher 
hydrophilicity and also explaining their properties on p-Gp and βIII overexpressing 
cells and on mutant cells. 
 The effect of the compounds on the microtubular network is different from 
those observed with the classical (docetaxel and paclitaxel) taxanes, inducing different 
bundling in cells with microtubules being very short, indicating a very fast nucleation 
effect and reflecting their high assembly induction power. 
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Introduction 
One of the main problems in the chemotherapeutic treatment is the development 
of resistance to the compounds used. Although many tumours show a favourable 
response in the early stages of treatment, after exposure to the chemotherapeutic agents, 
the tumour often develops resistance to the treatment.  Antitumour agents targeting 
tubulin have a great efficacy in the treatment of solid (paclitaxel, docetaxel, 
ixabepilone) or blood (vinblastine, eribulin) cancers,1-3 however, their highly systemic 
toxicity compromises the treatments based on these agents. Nevertheless, these 
compounds have also an advantage over the kinase inhibitors.4-5 Since they block 
tubulin which is involved in several essential cell functions and is a major constitutive 
protein, there is no possible alternative pathway to substitute the functions of tubulin 
(the main reason for the development of resistance against kinase inhibitors6-7). Thus, 
resistance through alternative pathways is not possible in the case of these compounds.  
Resistance to antitumoral agents targeting tubulin is possible through three 
different mechanisms:8 (a) overexpression of membrane pumps, (b) mutations in the 
ligand binding site and (c) overexpression of tubulin isotypes less sensitive to the drug 
employed.  
One of the membrane pumps usually involved in resistance to taxanes is p-
Glycoprotein (p-Gp), a protein involved in detoxification mechanism. It is assumed that 
its major role is to restrict the entrance of toxics through the gastrointestinal track or to 
prevent their access from blood stream to fetus and sensitive organs such as brain and 
testis.9 In cells overexpressing p-Gp, two opposite mechanisms control the intercellular 
concentration of drug, i.e., p-Gp decreases the internal concentration of a drug to reduce 
its effective cytotoxicity, but on the other hand, the target protein binds to a drug with 
high affinity to accumulate the drug inside the cell. The effectiveness of these resistance 
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mechanisms depends on the relative affinity of a drug to p-Gp and the target. An 
increased affinity to the target or a decreased affinity to p-Gp will overcome p-Gp-
mediated resistance.10 
The effect of variations in the affinity of taxanes on the resistance level of p-Gp 
overexpressing cells have been previously studied in our group and reported.10-11 These 
studies have shown that very high affinity taxanes (chitax-40) are able to overcome p-
Gp-mediated resistance. The same effect has been observed for other compounds which 
bind covalently to tubulin.12-14 
Second-generation taxanes with modifications at C2, C3’N and C10 positions 
have also been shown to be extremely effective against cells resistant to taxanes by p-
Gp overexpression.15-17 Although there were previous studies on the relation of changes 
in the taxane structure with their biological activities,18-19 measurements of the 
microtubule-taxane binding affinities have been performed only recently, which allows 
a rigorous examination of the relationship between binding affinity and cytotoxicity in 
drug-sensitive cells and drug-resistant cells overexpressing p-Gp.10,20-21 The study of the 
relationship between binding affinity and cytotoxicity (Figure 5) by Matesanz et al. in 
200810 indicates that there are factors that modulate the cytotoxicity in cells although 
both variables are related, i.e., there are compounds showing cytotoxicities on sensitive 
cells higher than expected from their binding affinity (paclitaxel, docetaxel, chitax-18), 
while some compounds exhibit higher cytotoxicity on resistant cells than those 
predicted from their binding affinity (chitax-19, chitax-21, chitax-35). 
The second way that tumour cells resists paclitaxel and its derivatives is by 
changing their tubulin. Although it is difficult for human cells to mutate in response to a 
chemical agent, it is possible for them to use the genetic diversity of the tubulin isotypes 
to reduce its sensitivity to certain compounds. Most vertebrate isotypes fall into six 
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categories, i.e., βI, βII, βIII, βIV, βV and βVI,22 with most of the differences in the 
clusters 124-129 and 237-240, as well as the C-terminal sequence. Although all 6 
isotypes are able to carry out two of the three canonical functions of microtubules 
(forming the mitotic spindle and the interphase network), the strong conservation of the 
tubulin isotypes implies that they should have specific individual functions. From these 
isotypes, βΙΙΙ is the one mostly involved in resistance to chemotherapy. βIII differs from 
the other main tubulin isotypes, βI, βII, and βIV, with the changes S126C and C241S, 
and in the presence of a lysine and a phosphorylated serine at the C-terminal.23 
βII, βIII, βIV isotypes have been isolated from bovine brain24 and it was found 
that the properties of the αβIII dimer differs significantly from the other two in the 
binding of several microtubule modulating agents.25 It was also found that the αβIII 
microtubules are less prone to inhibition of their dynamic behavior by docetaxel.26 Cells 
overexpressing βIII tubulin are resistant to paclitaxel,27 and it is known that high levels 
of βIII tubulin are found in docetaxel-resistant tumors. Thus, overexpression of βIII 
tubulin is an important prognosticator for the development of drug resistance.28-31 
There are different hypotheses to explain the molecular basis of paclitaxel-
resistance due to overexpression of βIII tubulin. Two plausible explanations are: (a) 
αβΙΙΙ dimers are the ones that are most dynamic,26 so that the cell compensates for the 
decrease in dynamics due to microtubule-stabilising agents by increasing the amount of 
these dimers, and (b) there are small but critical differences in the pore type I site (the 
initial external site for the binding of microtubule-stabilising agents on their way to the 
luminal site) between βI and βIII tubulins.12,32 Some difference in the pore type site I 
should result in a lower binding affinity to the initial pore site and then much lower 
internalization rate towards the inner site33, which may cause weakening of microtubule 
stabilisation. 
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Finally, it has been observed that mutations in β-tubulin rapidly appear at the 
paclitaxel or laulimalide binding sites34-36 in cell cultures exposed to microtubule-
stabilizing agents, which suggests that a mutational mechanism of resistance is possible. 
However, despite early reports on the relevance of tubulin mutations in patients with 
non-small cell lung carcinoma,37 sequencing of tumors does not show any evidence that 
β-tubulin mutations could play a major role in the resistance of tumors to taxanes.38-44 
Nevertheless, a few mutations41, 45-46 have been found to result in effective resistance of 
the mutated cells to paclitaxel.47 This finding indicates that these mutations can play an 
effective role in some specific cases and thus drugs that are effective against tumors 
mutated in the β-tubulin gene could be of clinical interest. 
In this paper we investigate the reasons for the effectiveness of a series of 
modified taxanes previously reported to be highly effective on p-Gp-overexpressing 
cells15,16,17 by performing complete characterizations of their cellular effects, as well as 
their interaction with microtubules. These characterizations include the assessment of 
the NMR, thermodynamic and biochemical parameters of the microtubule assembly, 
and the analysis of the structural effects of these taxanes on microtubules using small 
angle X-ray scattering.  
 
Materials and Methods 
Ligands and chemicals 
Chitax-4 and chitax-40 were synthesized as previously reported.10 SB-T-1102, 
SB-T-1214, SB-T-12854 and SB-T-121303 were synthesized using the methods 
previously reported.15-17 Flutax-2 was synthesized as previously described.48 Epothilone 
B was a kind gift from Prof. Karl-Heinz Altmann (ETH, Zürich). The rest of the 
chemicals employed were commercially available with analytical grade or better. 
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Human cell methods.  
Cytotoxicity evaluation was performed with A2780, A2780AD, (overexpressing 
p-Gp)
49
 , PTX10, PTX22, A8 (A2780-derived)50 human ovarian carcinoma cell lines, 
Hela and Hela βIII transfected cells51 with the MTT assay modified as previously 
described.11 Indirect immunofluorescence was performed in A549 cells52 that had been 
cultured overnight in 12 mm round coverslips and incubated further for 24 h in the 
absence (drug vehicle: DMSO) or in the presence of different ligand concentrations. 
Attached cells were permeabilized with Triton X100 and fixed with 3.7% 
formaldehyde. Microtubules were specifically stained with DM1A α-tubulin 
monoclonal antibodies and DNA with Hoechst 33342 as previously described.53 The 
preparations were examined using a Zeiss axioplan epifluorescence microscope and the 
images were recorded in a Hamamatsu 4742-95 cooled CCD camera. Cell cycle 
analysis was performed as previously described.54 
 
Tubulin preparation and tubulin assembly induction measurements.  
Calf brain tubulin was purified as described in the literature.55 Glutaraldehyde-
stabilized microtubules with active paclitaxel binding sites were prepared as 
described.32 Critical tubulin concentrations of tubulin in PEDTA4-GTP (10 mM sodium 
phosphate, 1 mM EDTA, 4 mM MgCl2, 1 mM GTP, pH 6.7) in the presence of ligands 
were measured as previously described.54 The polymers formed were adsorbed onto 
formvar/carbon coated copper grids, stained with 1% uranyl acetate, and observed with 
a JEOL 1230 electron microscope operated at 100 kV and equipped with a Gatan 
Bioscan 702 CCD camera. 
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Binding of taxanes to unassembled tubulin and microtubules. 
The binding constants of SB-T-1102, SB-T-1214 and SB-T-12854 were 
measured as previously described.56 To measure the binding affinity of SB-T-121303, 1 
mL samples of 1 µM glutaraldehyde-stabilized MTs, 1.1 µM Epothilone B and 1.1 µM 
of SB-T-121303 in GAB (glycerol assembly buffer; 3.4 M glycerol, 10 mM sodium 
phosphate, 6 mM MgCl2, and 1 mM EGTA pH 6.5) with 0.1 mM GTP were incubated 
for 30 min at the desired temperature in polycarbonate centrifuge tubes (Beckman 
Coulter, Inc., Fullerton, CA). The samples were then centrifuged at 90,000 g for 20 min 
at the desired temperature in a TLA-100.2 rotor employing a Beckman Optima TLX 
ultracentrifuge. 
The supernatants were collected by pipetting, and the pellets were resuspended 
in 10 mM phosphate buffer (pH 7.0). One micromolar paclitaxel was added as the 
internal standard. Both the pellets and the supernatants were extracted three times with 
an excess volume of dichloromethane, dried in vacuo, and dissolved in 30 µL of 
methanol. The samples were analyzed by HPLC. Binding constants for compounds 
reversibly displacing flutax-2 or epothilone B were calculated using Equigra v557. The 
thermodynamic parameters (apparent ∆G0, ∆H0, and ∆S0) were calculated as 
previously described.54  
The binding of the compounds to unassembled tubulin was measured by 
ultracentrifugation. Samples (200 µL) containing 50 µM tubulin and 50 µM compound 
in 10 mM Sodium Phosphate and 0.1 mM GTP at pH 7.0 were incubated for 20 min at 
25ºC, centrifuged at 100,000 rpm for 2 h at 25 ºC in a TLA100 rotor, and the upper half 
and lower half of the solution as well as pellet were separated. Then, 25 µL of each 
sample was taken, diluted to 1:20 with 10 mM sodium phosphate 1% SDS at pH 7.0, 
and the tubulin concentration in each part of the tube was measured by absorbance at 
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275 nm.58 Paclitaxel (5 µM, internal standard) was added to the rest of the samples and 
the samples were extracted three times with 1 volume of dichloromethane, dried, 
redissolved in 30 µL methanol/water, and analyzed with an Agilent 1100 series HPLC, 
employing a ZORBAX Eclipse XDB-C18 column and acetonitrile/water gradient from 
50 to 80% at 1 mL/min in 30 min. 
 
Preparation of NMR samples. 
SB-T-12854 (300 µM) was added to a 20 µM solution of tubulin in 10 mM KPi 
with 0.1 mM GMPCPP and 6 mM MgCl2 at pH 6.7 (effective measurement of a pH 
meter in the D2O buffer) prepared as previously described.59 
 
NMR Experiments 
 NMR spectra were recorded at 310 K (polymeric tubulin samples) in D2O on a 
Bruker AVANCE 500 MHz spectrometer as previously described.59 STD and TR-NOE 
experiments were performed also as previously described59.  
 
Conformational search and docking of ligands.  
The paclitaxel derivative structures were built from the paclitaxel template based 
on electron crystallography and NMR TR-NOESY experiments.60 The internal binding 
site structure was taken from 1JFF,61 while the external binding site used the one 
previously reported by us.60 The βIII binding site was constructed by homology 
modeling from 1JFF. SB-T-1102, SB-T-1214, SB-T-12854, SB-T-121303 and 
paclitaxel were docked in both the internal and external sites of microtubules as 
previously described.60 Structures located in the internal site were minimized using 
Macromodel 9.6, with several steps of Polak-Ribière conjugate gradient (PRCG) until 
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the energy gradient became lower than 0.005 kJ Å-1 mol. The poses in the external 
binding site of microtubules were refined by using molecular dynamics (MD) 
simulations performed with AMBER 11 (500ps equilibration time and 1ns acquisition 
time). For each compound, 100 structures were saved along the last nanosecond of the 
MD trajectory. 
The expected STD effects of SB-T-12854 bound to microtubules were 
calculated using the CORCEMA-ST program.62 For these full relaxation matrix 
calculations, the overall rotational motion correlation time τc for the free state was 
always set to 0.75 ns (values between 0.25 and 1 ns were tested), since NOESY cross 
peaks for the free molecule were basically zero at room temperature and 500 MHz. The 
τc value for the bound state was set to 60 ns for non-polymerized α/β-heterodimers (τc 
estimated with HYDROPRO63) and 100 ns for microtubules (optimized in the 
CORCEMA-ST calculation). An order parameter, S2 = 0.85, was employed to account 
for the fast rotation of the methyl groups, as implemented in CORCEMA-ST.  
In order to fit the experimental STD effects and TR-NOE intensities, off-rate 
constants between 5-100,000 s-1 were tested. Optimal agreement was achieved using koff 
= 100 s-1. Conformational search calculations were performed using the 
MacroModel/Batchmin64 package (version 9.6) and the OPLS2005 all-atom force field 
as previously described.59 
 Docking of the ligand was performed using the AutoDock 4.0 program,65 
employing the additional CORCEMA-ST66-based scoring function as previously 
illustrated.59 The predicted STD values of each structure were obtained with 
CORCEMA-ST and the structure of lowest energy value of these 100 structures was 
considered for comparison against the experimental data. 
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X-ray scattering measurements. 
 Tubulin was equilibrated in 10 mM sodium phosphate buffer with 1 mM EDTA 
and 0.1 mM GTP at pH 7.0 through a Sephadex G-25 medium column (25x9 mm), and 
the protein was centrifuged for 20 min at 90,000xg in a TLA120.2 rotor in a Optima 
TLX centrifuge (Beckman) to remove aggregates. The tubulin concentration was then 
determined spectrophotometrically as previously described.58 MgCl2 (7 mM) and up to 
1 mM GTP were added to the sample (final pH 6.7) and the desired ligand or DMSO 
(vehicle) in a 10% stoichiometric excess over the protein concentration was added. The 
samples were incubated for 20 min at 37 ºC and kept at 25 ºC before recording the 
scattering patterns. 
SAXS data collection was performed on a Bruker NANOSTAR system coupled 
to an X ray tube (λ = 1.54Å), wherein the camera was set to cover the scattering vector 
range, defined as reciprocal Bragg spacing i.e. s = 2 sin θ/λ, from 0.013 to 0.22 nm-1. 
Calibration of the scattering vector was obtained by reference to the orders of 
diffraction of silver behenate.67 The temperature of the samples was set to 25 ºC and the 
X-Ray scattering profile was recorded for 2 h in 30-min frames with a Bruker Hi-Star 
multiwire area detector. Data analysis was performed using the Bruker software 
provided or the FIT2D software package provided by ESRF 
(http://www.esrf.eu/computing/scientific/FIT2D/). Raw data were normalized for the 
incoming intensity and detector response before averaging and subtracting the buffer 
scattering pattern. Time frames in which the data significantly differed from the original 
pattern due to radiation damage were removed before averaging. 
The low angle X-ray scattering pattern of microtubules in solution can be 
described as the Fourier transform of a hollow cylinder. To a first approximation, the 
intensity is given by the zero’th order Bessel function , q being the scattering ( )
2
0J qR
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angle and R, the cylinder radius.68 The position of the first scattering maximum is 
therefore a sensitive measure for the radius of the microtubule, via relation J01 = 
(1.22/2R), since these are not distorted in a solution scattering pattern due to overlap 
between the higher order diffraction maxima of the helical lattice69-70 
The differences in diameter between microtubules assembled in the presence of 
different taxanes can be interpreted, to a good approximation, as changes in the average 
number of protofilaments making up the cylinder wall. 
 
RESULTS 
Cell biology 
In order to have a rigorous comparison between the cytotoxicity of the 
compounds and those previously determined,10 the compounds were tested for their 
cytotoxicity under the same conditions against the same cell lines (Table I). The 
compounds showed a very good activity on A2780AD cells (resistant to paclitaxel by 
the MDR mechanism), hence confirming all previous results.15-17 
Then, we wanted to know if the compounds were also effective in cells resistant 
to paclitaxel by other mechanisms (mutations in the β-tubulin binding site and 
overexpression of βIII-tubulin isotype). The compounds showed a very good activity in 
cells overexpressing βIII-tubulin isotype (Table II). While βIII-tubulin transfected HeLa 
cells have a resistance index of 11 against paclitaxel, the resistance index is decreased to 
2.5 for SB-T-1102 and to 5.3 for SB-T-1214. Moreover the modified cells are neither 
resistant to SB-T-12854 (R/S 1.4) nor to SB-T-121303 (R/S 0.8). A similar result was 
obtained for the toxicity of the compounds in cells mutated in the paclitaxel binding 
site. PTX10 cells and PTX22 cells are A2780 cells resistant to paclitaxel through 
mutations in the paclitaxel binding site F272V and A366T, while A8 are resistant to 
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epothilone through another mutation T276I (involved in the interaction with the thiazole 
side chain of epothilone71) but not to paclitaxel.50 While PTX10 and PTX22 are 
resistant to paclitaxel with resistance indexes of 20.8 and 8.4, respectively, they are 
sensitive to all compounds assayed (Table III).  
The results are fully compatible with those previously published for p-Gp-
overexpressing cells and indicate that these taxanes are able to overcome resistance by 
all known mechanisms. It is worth mentioning that the compounds do not have a large 
increase in cytotoxicity as compared to paclitaxel (in fact they are less cytotoxic than 
paclitaxel in the A2780 and Hela non-resistant cells). This is compatible with previously 
reported results,10 which indicate that a minimal amount of ligand molecules should be 
bound to the cellular microtubules to produce the cytotoxic effect. Thus, the drug 
concentration should be over a certain minimum which is the minimal IC50 that can be 
measured with the method employed. As shown in Figure 5A of Matesanz et al.,10 the 
maximum cytotoxicity in A2780 cells possible for taxanes under the condition of the 
experiment is in the order of nM. 
We also studied the effects of the compounds in the cell cytoskeleton and in the 
cell cycle (Figure 2) to compare them with paclitaxel and docetaxel. The 
immunofluorescence experiments indicate a differential effect of the SB-T taxanes, 
chitax-4 and chitax-40.  Although all compounds arrest the cell cycle at G2/M (Figure 
2, lower panel), the morphology of the changes induced in the cytoskeleton is different 
from those induced by paclitaxel. (Note: SB compounds, chitax-4 and chitax-40 cause 
the cell cycle arrest at similar concentrations for A2780 and A2780AD cells, which 
confirms the IC50 results.) While paclitaxel (Figures 2C, 2E and 2G) induces the typical 
MSA bundles of microtubules which accumulate close to the membrane and the 
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nucleus, the SB-T compounds, chitax-4 and chitax-40 induce micronucleated cells with 
much shorter microtubule bundles distributed all over the cytoplasm.  
 
Effects on tubulin assembly. 
 To seek the reasons for the high activity of the compounds in cells resistant to 
classical taxanes, we studied the biochemistry of their interactions with their target 
tubulin. It has been shown that SB-T-1102, SB-T-1214, SB-T-121303 and SB-T-12854 
are extremely effective in increasing the rate of microtubule assembly. In the presence 
of these taxoids the assembly rate (even in the absence of GTP in the media) is 
dramatically greater than that in the presence of paclitaxel or GTP.16-17 Also, the 
assembly proceeds without an appreciable induction period and is complete within 2 
min. Since the assembly induction in this work16-17 was monitored by turbidity and this 
technique was affected by the morphology of the polymers, we wanted to know if the 
effect of these compounds on the microtubule assembly was limited to an increase in 
the rate of the assembly or if it also increased the mass of polymer formed. Thus, we 
tested the critical concentrations of tubulin required for assembly induction in the 
presence of the compounds using centrifugation and quantification of the polymer 
formed. All ligands induced tubulin assembly with much higher potency than paclitaxel 
and docetaxel, indicating that not only the rate of assembly was faster but also more 
polimer was formed (Table IV).  
 
Binding constant and thermodynamic parameters of the binding of the compounds to 
microtubules and dimeric tubulin. 
In order to correlate the observed cytotoxic effect of the compounds with their 
affinity constant to microtubules, the binding constants of SB-T-1102, SB-T-1214 and 
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SB-T-12854 at different temperatures were measured using the flutax-2 displacement 
method54,56 (Table V). Since the binding constant of SB-T-121303 exceeded the 
sensitivity of the flutax-2 displacement test,57 its affinity constant was obtained using 
the epoB displacement method10 (Table V). 
Using the binding affinity data, the thermodynamic parameters of the 
interaction, i.e., free energy of the binding (∆G) and the enthalpy (∆H) and entropy (∆S) 
contributions to ∆G (Table VI), could be calculated. 
The effect of single substituent changes on the binding affinity of the 
compounds could easily be quantified. The change at C13, which eliminated the aryl 
group at position C3’ and introduced an isobutyl moiety resulted in no change in the 
binding affinity, i.e., SB-T1102 (2.4±0.3x107 M-1) was found to have nearly the same 
binding constant at 35ºC as that of paclitaxel (1.43±0.17x107 M-1) and docetaxel 
(3.93±0.27x107 M-1) (∆∆G SB-T1102:paclitaxel = -1.4 kJ mol-1; ∆∆G SB-
T1102:docetaxel = +1.3 kJ mol-1). SB-T-1102 behaves thermodynamically in a manner 
similar to the other reversibly binding taxanes, wherein its binding affinity decreases 
with increase in temperature. However, the decrease in its binding affinity with increase 
in temperature is much less marked than other taxanes. The result indicates that its 
binding is much less exothermic with a large decrease in the enthalpy of binding (∆HSB-
T1102 = -8±3 kJ mol-1 vs. -42.1±0.3 kJ mol-1 for paclitaxel and -44.8±0.2 kJ mol-1 for 
docetaxel), but this decrease in the enthalpy of binding is compensated by a substantial 
increase in the entropy of binding (∆SSB-T1102 = -115±11 kJ mol-1 K-1 vs. -29±13 kJ mol-
1
 K-1 for paclitaxel and -26±8 kJ mol-1 K-1 for docetaxel), which suggests significant 
differences in the binding mechanism.  
 Since SB-T-1214 contains two structural differences as compared to SB-T1102 
and docetaxel, it is not possible to directly compare the effect of the introduction of the 
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double bond in the 2-methylpropenyl moiety at C3’ on the binding affinity with that of 
an isobutyl or phenyl moiety. However, the effect is positive on the binding affinity, 
i.e., SB-T-1214 (8±3x107 M-1) has twice the binding affinity of docetaxel, three times 
that of SB-T-1102 and five times that of paclitaxel at 35 ºC (∆∆G SB-T-1214:docetaxel 
= -1.8 kJ mol-1; ∆∆G SB-T-1214:SB-T-1102 = -3.1 kJ mol-1). Given the contribution of 
the substituents in position C10 (lower than 2 kJ mol-1),10 it is not possible to distinguish 
which one of the modifications, i.e., the 2-methylpropenyl moiety at C13 or the 
cyclopropanecarbonyl moiety at C10, is responsible for the increase in the binding 
affinity. The comparison of SB-T-1102 and SB-T-1214 with compounds with single 
point modifications,15 indicates that, for both of them, the cytotoxicity decreases when 
the double bond is reduced and when the acetyl group is replaced by a 
cyclopropanecarbonyl group, which suggests that the favorable contribution to the 
binding arises from the 2-methylpropenyl group. Interestingly, the binding profile of 
SB-T-1214 is substantially different as compared with SB-T1102. The binding process 
becomes more endothermic similar to classical taxanes (∆HSB-T1214 = -32±2 kJ mol-1 vs. 
-8±3 kJ mol-1 for SB-T1102; -42.1±0.3 kJ mol-1 for paclitaxel; -44.8±0.2 kJ mol-1 for 
docetaxel), while keeping a strong entropy contribution (∆SSB-T1214 = 47±6 vs. 115±11 
kJ mol-1 K-1 for SB-T1102; -29±13 kJ mol-1 K-1 for paclitaxel; -26±8 kJ mol-1 K-1 for 
docetaxel). 
The further introduction of fluorines or a double bond does not significantly 
modify the binding parameters of taxanes. Compound SB-T-1285417 binds to 
microtubules in a manner very similar to SB-T-1214 (∆∆GSB-T-12854:SB-T-1214 = -0.5 kJ 
mol-1, ∆HSB-T12854 -28±3 kJ mol-1, ∆SSB-T12854 64±10 kJ mol-1 K-1), indicating a weak 
influence of the fluorine atoms on the binding.  
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Finally, the highest affinity compound, SB-T-121303,16 was studied. This 
compound closely resembles chitax-40 with a high activity with MDR cells10. This 
taxane has a methoxy group at the meta position of the C-2 benzoate instead of an azido 
group in chitax-40 and 2-methylpropenyl in the C13 side chain instead of a phenyl 
group in chitax-40. Concomitantly its thermodynamic profile of binding to tubulin is 
nearly identical to that of chitax-40, i.e., ∆HSB-T121303 = -33±2 kJ mol-1 vs. -26±24 kJ 
mol-1 for chitax-40; ∆SSB-T121303 = 77±7 vs. 99±80 kJ mol-1 K-1 for chitax-40). 
It is difficult to know the exact contribution of the structural changes on the 
binding affinity because there are at least two differences between the compounds and 
any other taxanes analyzed, but if we consider the differences in binding energy to the 
paclitaxel site, the effect of the modifications at C10 appears to be negligible.10 The 
observed effects of structural changes on binding affinity can be quantified as follows: 
(i) 3´-Aryl  3´-isobutyl = +1.3 kJ mol-1; (ii) introduction of the double bond is slightly 
favorable in terms of binding based on 3´-Aryl  3´-(2-methylpropenyl) = -1.8 kJ mol-1 
(docetaxel  SB-T-1214); (iii) further introduction of a –OCH3 group at  the meta 
position of the C2 benzoyl group results in a large increase of the free energy of binding 
(nearly -10 kJ mol-1), which arises from an entropic contribution similar to that 
described previously10 for the introduction of a methoxy or azide substituent at this 
position; (iv)  introduction of fluorines does not have any appreciable effect on binding 
affinity, i.e.,  3´-(2-methylpropenyl)  3´(2-difluorovinyl) = -0.5 kJ mol-1 (SB-T-1214 
 SB-T-12854). 
In order to examine if the fast nucleation effect may come from higher affinity 
of the compounds to unassembled tubulin, the binding of chitax-4, chitax-40, SB-T-
1102, SB-T-1214 and SB-T-12854 to dimeric tubulin was studied. Under the conditions 
of the study (50 µM tubulin and 50 µM compound), we were unable to detect 
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accumulation of taxanes in the lower part of the centrifuge tube, which indicates that 
their binding constants to dimeric tubulin are lower than 103 M-1, as in the case of 
classical taxanes.72 
 
NMR studies. 
The bound conformation of the highly active C3’-substituted family of taxanes 
was studied, employing SB-T-12854. STD-NMR experiments are widely employed to 
detect ligand binding to protein receptors and to characterize the ligand binding epitope, 
while TR-NOESY experiments are used to assess the conformational features of the 
compound bound to microtubules (it is worth mentioning that these techniques require 
particularly fast kinetic conditions of the interaction. Thus, very slow dissociating 
ligands cannot be studied with these techniques).73-74 Both the TR-NOESY spectra of 
the compound bound to microtubules which would provide the bioactive conformation 
(Figure 3A) and the STD spectra which would provide the binding epitope (Figure 3B) 
were obtained, although the signals obtained were of low intensity, as expected from a 
compound with a high affinity to the target and thus with slow dissociation kinetics. 
The TR-NOESY data showed clearly cross peaks between the benzoyl protons at 
ortho position with respect to the esther group and the tert-butyl protons of the side 
chain, indicating that the bound conformation is essentially identical to that previously 
determined for docetaxel10 and thus this conformation could be used to build the 
structures of the taxanes examined. 
 
NMR-guided modeling of the bioactive conformations. 
The STD and TR-NOESY data were then employed to derive a detailed 3D 
model for the tubulin-bound conformations of the ligands. Although the intensities of 
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the cross peaks were weak, the STD information obtained allowed us to model SB-T-
12854 into the pore binding site as previously described.59 NRMSD of the STD fitting 
was 14.4%, which is excellent and indicates that the compound fits in the pore binding 
site in the same way as docetaxel does (Figure 4A). 
Considering that the conformation and fitting in the pore binding site are 
identical to those described for docetaxel, it is reasonable to hypothesize that the 
interaction of the compounds with tubulin may be essentially identical to that previously 
described.59 The taxanes in this study were thus docked into the binding site and the 
interaction was optimized (Figures 4B-E) in order to seek the reasons for their increased 
assembly induction power, which was the main cellular and biochemical difference 
observed. Recent crystallographic data71 indicate that microtubule-stabilizing agents of 
the paclitaxel site induce microtubule assembly using an allosteric mechanism. They 
bind to the paclitaxel binding site, inducing a strong stabilization of the S7-H9 loop (M-
loop). This loop is involved in contacts with the H2-S3 and the S2-S2´ loops of the 
adjacent subunit, and this stabilization results in stronger lateral contacts between 
adjacent subunits, leading to microtubule stabilization. 
From the comparison of potency of the compounds in assembly induction, the 
compound with an acetyl group at C10 (paclitaxel) exhibits the weakest assembly 
induction power (higher Cr) of 4.2 µM. SB-T1102, the compound with the acetyl group 
at this C10 position, also shows the worst Cr (1.6 µM) in the series of taxanes examined 
in this study. The compound with fluorines, SB-T-12854, exhibits the strongest 
assembly induction power with Cr 0.3 µM. 
 
Effect on microtubule structure. 
In order to examine the effect of the compounds on microtubule structure, the 
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diameter of the ligand-induced microtubules was measured using SAXS.60, 69-70 The size 
of all induced microtubules (Figure 5) were between those of paclitaxel and docetaxel, 
with an average number of protofilaments ranging between 13.2 (SB-T-1214) and 13.9 
(SB-T-12854) (Table VII). 
In a previous paper60 we reported that the diameter of taxane-induced 
microtubules was dominated by the substituents at C7 and C10. We have observed that 
bulky groups at C7 increase the number of protofilaments of microtubules, while bulky 
groups at C10 decrease the number of protofilaments. However, modifications at C13 
have little or no effect on microtubule structure, while the introduction of an azide 
group at the meta position of the phenyl ring at C2 slightly increases the microtubule 
diameter. 
All the compounds examined have small substituents at C10 and subsequently 
induce microtubules with smaller diameter than that of docetaxel, which does not have 
substituents at C7 and C10. Also, as expected from the introduction of the methoxy 
group at C2, SB-T-121303 induced the microtubules with the largest diameter observed. 
However, none of the taxanes studied induced a major modification in the structure of 
the microtubules, which indicates that the effect on the structure is not the cause of the 
higher activity observed. Nevertheless, the fact that the changes in the structures reflect 
the same pattern as those previously reported10 reinforces the hypothesis that the 
interaction of the compounds with the binding site is essentially the same as that of 
other taxanes. 
    
Discussion 
We have studied the differences in the cellular effects and the interaction with 
microtubules for a series of taxanes highly active in MDR cells, with the intention to 
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unveil the characteristics that result in the ability to overcome all known mechanisms 
employed by tumour cells to resist taxanes (p-Glycoprotein-mediated multidrug 
resistance, mutations in the taxane binding pocket at β-tubulin, and βIII tubulin isotype 
overexpression). 
 
Celular and biochemical differential effects of the SB-T compounds. Structural 
basis for the higher assembly induction power. 
Three biochemical and biophysical parameters for the interaction of the 
compounds with microtubules, i.e., (a) their binding affinity for the paclitaxel site, (b) 
their potency for inducing tubulin assembly under conditions in which tubulin is not 
able to assemble by itself, and c) their effect on the structure of the microtubules, have 
been characterized with the intention to find out which one of these parameters explains 
the activity of the compounds in resistant cell lines. 
The main difference in the cellular effects is the morphological changes induced 
in the cytoskeleton which are different from those induced by paclitaxel. While 
paclitaxel (Figures 2C, 2E and 2G) induces the typical MSA bundles of microtubules 
which accumulate close to the membrane and the nucleus, the compounds studied 
induce much shorter microtubule bundles distributed all over the cytoplasm. These 
differences in morphology suggest a much faster and intense assembly induction by the 
taxanes examined. 
Concerning the biochemical parameters of the taxane-site interaction, the two 
main significant differences observed are the higher assembly induction power as 
compared with classical and other high affinity taxanes (as expected from the cellular 
results), and the higher entropic contribution to the free energy of binding. 
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From the comparison of the entropy changes of taxane-binding previously 
obtained,10 it has been found that the entropy change in the binding process is 
determined by two parameters, i.e., the hydrophobicity of the ligand and the molecular 
volume which determines the entropy of the bound ligand. When the volume of a 
certain side chain is decreased and the functional group incorporated has more sp3 
carbons, the conformational freedom of the side chain increases which leads to the 
increase in the entropy of the bound species. This is the case for all the SB-T 
compounds examines, in which the phenyl moiety at the C13 side chain has been 
replaced with an aliphatic side chain, which justifies the higher entropic contribution to 
the free energy of binding. 
The comparison of the binding affinities of the taxanes assayed with the 
observed assembly induction power (Cr) shows that all the SB-T compounds assayed 
induce tubulin assembly much more effectively than paclitaxel and docetaxel as well as 
the high-affinity taxanes, chitax-4 and chitax-40. Since the main biochemical effect 
observed is a large increase in assembly induction power, we examined the NMR-
directed models to seek the structural reason for the high assembly induction power.  
Recent structural data have shown that the main structural effect of taxane-
binding site ligands (zampanolide and epothilone)71 is the strong structural stabilization 
of the S7-H9 loop (M-loop). This loop is disordered in the absence of ligand and 
becomes structured in the presence of ligands. The models indicate that the 
conformation and binding mode of the high potency taxanes remain unchanged (Figure 
4 A-F), and thus only minor changes in the H-bonding and conformation in the binding 
pocket would occur. The main difference between the structure of the binding site in the 
zampanolide- or epothilone-bound tubulin71 and the model of paclitaxel-bound tubulin 
in the luminal site (Figure 4b) is the formation of an H-bond between the carboxyl 
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group at C10 and R284. In the crystal structure determined by Prota et al.71 (4I4T), this 
residue is involved in interactions with the H9 loop, stabilizing the structure of the M-
loop. Although there is not yet any crystallographic structure of tubulin with a taxane 
molecule in the binding site, it is logical to assume that the main structural effect of the 
taxanes would be the stabilization of the M-loop and that the differences in assembly 
induction power should be related to differential influences on the M-loop. 
The main chemical differences between paclitaxel and the ligands studied are 
related to the C13 side chain and the C10 moiety. From the ligands studied, SB-T-1102 
is the one with the lowest affinity (similar to paclitaxel) and also with the lowest 
assembly induction power (although still significantly higher than that of paclitaxel). In 
this case, the structural differences with paclitaxel are in the C13 side chain which has 
aliphatic groups instead of aryl moieties, while the group at C10 is an acetyl group that 
is same as that in paclitaxel. The main visible difference in the binding site is the slight 
rotation of the ligand which disrupts the H-bond with R284, inducing a different 
conformation to the M-loop. The same effect is observed in the more powerful ligands, 
SB-T-1214 (Figure 4C) and SB-T-12854 (Figure 4D), in which a bulkier substituent at 
C10 points toward the luminal space of the microtubule. The last ligand, SB-T-121303 
(Figure 4F), has the highest binding affinity, but is not the one with the highest 
assembly induction power. In this case, the binding pose is dominated by the interaction 
of the methoxy group at the meta position of the benzoyl group at C2 with H229, as in 
the case for chitax-40,60 wherein the interaction with R284 is also formed, but the M-
loop has the same conformation as that in the presence of paclitaxel. 
From the data available, we propose that the enhancement of the tubulin 
assembly power is caused by (i) the different interactions of the compounds with the M-
loop, resulting in higher potencies in the absence of the interaction with R284, and (ii)  
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by the higher binding affinity to the site (in the case of SB-T-121303),  as observed in 
the cases for other MSAs (Figure 4).54 The compounds that do not interact with R284 
(SB-T-1102, SB-T-1214 and SB-T-12854) have much higher assembly induction 
potency than the classical taxanes, as well as high-affinity taxanes (chitax-4 and chitax-
40), although these compounds have affinities to the binding site similar to that of 
paclitaxel. SB-T-121303, with 50 times higher binding affinity by interacting with 
R284, is significantly less potent in inducing microtubule assembly than SB-T-12854. 
 
Rationalization of the effect of the compounds on resistant cells. 
How could these changes observed be related to their effect on resistant cells? 
From the view point of the p-Gp-mediated multidrug resistance, which is not tubulin 
mediated, the effect can only be ascribed to either an increase in affinity to tubulin (high 
affinity compounds or covalent binders to tubulin are able to overcome p-Gp-mediated 
MDR in tumoural cells10, 12, 75) or to a decrease in affinity to the membrane efflux pump. 
The former cannot be the case, because the effects of SB-T-1102, SB-T-1214 and SB-T-
12854 have similar or only slightly higher binding affinities than paclitaxel and 
docetaxel, except for the case of SB-T-121303, which has a very high affinity to tubulin 
due to the meta-methoxy group in the C2 benzoyl moiety. 
Lower R/S ratios have been previously observed for other medium-affinity (Ka 
= 107 M-1) taxanes halogenated in the C2 benzoyl ring (chitax-30, 34 and 35: Ka = 
1.76x107 M-1, 1.20x107 M-1 and 0.88x107 M-1, respectively), and these compounds also 
have favorable entropic contributions to the free energy of binding, as observed in the 
cases of SB-T-1102, SB-T-1214, SB-T-12854 and SB-T-121303. Considering the 
structural changes in the substituents at positions C10 and C13, it is logical to propose 
that they should decrease the hydrophobicity of the compounds (as the introduction of 
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halogen atoms should do), this decrease in hydrophobicity may turn them into weaker 
substrates for p-Glycoprotein, which results in the same effect as that by the increase in 
the binding affinity for tubulin10 (see Supplemental Information). In this case, the 
binding affinity to tubulin is not modified because the lower entropic cost required to 
transfer a less hydrophobic ligand out of the water compensates the higher enthalpy cost 
for placing it into the hydrophobic binding pocket without affecting binding affinity to 
tubulin.  
For βIII-overexpressing cells, the effect has to be related to the binding affinity 
to the protein. The βIII-overexpressing cells have been shown to be resistant to 
palitaxel27 and high levels of βIII tubulin are found in docetaxel-resistant tumors.28-31 
However, there are no differences in the paclitaxel-binding site between βI (the major 
isotype) and βIII, the only changes observed there are S227A and C241S close to the 
binding site. These changes should result in a global change in the binding site, i.e., 
slightly displacing the global volume of the binding site towards the east (Figure 6). 
This change is due to the loss of the H-bonds formed between S277 and S280, as well 
as Q281 and a small opening of the loop directly in contact with the α-subunit due to 
the C241S mutation. This increase in space affects the position C13 in particular with 
the phenyl ring being displaced 2.5 Å towards the east inside a larger binding pocket 
(Figure 6).  This change should increase the desolvation energy for classical taxanes, 
decreasing their affinity. The effect can be compensated with an increase in affinity, 
since from the cytotoxicity data, high affinity compounds are able to overcome the 
resistance due to βIII-overexpression (chitax-4 and chitax-40). However the SB-T 
compounds studied are more effective in these cells than the chitax compounds with 
much higher affinity. The reason for this should be the larger entropic freedom of the 
side chain, which increases the entropy of the bound state and compensates the increase 
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in desolvation energy. In fact, the compound with the highest conformational freedom 
in the C13 side chain, SB-T-1102, is more effective in βIII-overexpressing cells than 
SB-T-1214 with lower conformational freedom. 
The SB-T compounds are also effective in PTX10 and PTX22 cells which 
contain mutations in the paclitaxel binding site, βF272V and βA366T. The effectiveness 
of compounds in the cells with mutation F272V can also be ascribed to their smaller and 
more flexible C13 side chain. F272 is directly involved in the interaction with the C13 
side chain (Figure 7). Thus, when it is changed to a smaller residue, the volume of the 
binding pocket (Figure 7 grey surfaces) increases by nearly 40 Å3, which leads to the 
increase in the desolvation energy of the binding. The smaller and flexible groups of the 
SB-T compounds at C13 compensate this effect by the entropy gain in the bound-state 
and thus it can overcome the resistance. 
Finally, the molecular modeling also indicates that the resistance of cells 
containing the A366T mutation is due to their indirect effect on the M-loop. The 
mutation results in two new interactions in the binding site, i.e., T366 with β−M295 and 
β−F319, as well as a steric repulsion with A273.  M295 is placed in the α-helix (H9), 
while A273 is in the β-sheet (S7) adjacent to the M-loop. Both new interactions should 
affect M-loop structure, decreasing the effect of paclitaxel on tubulin. Thus, we propose 
that the efficacy of the SB-T compounds in PTX-22 cells should be ascribed to their 
differential interaction with the M-loop, as well as their higher assembly induction 
power. 
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Table I.-Cytotoxicitya of the compounds employed in the study on the growth of  
nonresistant and resistant by p-Gp overexpression cells. 
 
Compuestos A2780 (nM) A2780AD 
(nM) 
R/S MCF7 
(nM) 
MCF7-R 
(nM) 
R/S 
Paclitaxel 0.4±0.1 1244±164 3110 1.7c 299c 176c 
Docetaxel 0.6±0.2b 290±16b 483b 1.0c 235c 235c 
Chitax-4 2.7±0.6b 14.0±3.8b 5.2b ND ND ND 
Chitax-40 7.0±1.0b 9.1±0.45b 1.3b 1.9±0.3d 153±11.6d 81d 
SB-T-1102 3.7±1 29.1±2.6 7.9 0.35c 2.8c 8c 
SB-T-1214 5.2±1.2 10.9±1.8 2.1 0.20c 2.1c 10.5c 
SB-T-12854 3.5±0.6 15.1±3 4.3 0.13e 4.3e 33e 
SB-T-121303 3.4±0.6 10.5±1.2 3 0.36f 0.33f 0.91f 
aIC50 values determined for this work (nM) are the mean ± SEM of three independent 
assays. 
bData from10 
cData from15 
dData from76 
eData from17 
fData from16 
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Table II. Cytotoxicity of different SB-T taxanes on the growth of human cervical 
carcinoma cells HeLa and β III transfected cell line (wild-type βIII) cellsa. 
Compound HeLa (nM) HeLa transfected (nM) R/Sb 
Paclitaxel 0.7±0.2 7.7±0.9 11 
Chitax-4 3.2±1.9 10.25 ± 1.9 3.2 
Chitax-40 9.2±0.3 16  ± 2 1.7 
SB-T-1102 4.4±1.0 11.2±2.6 2.5 
SB-T-1214 2.1±0.5 11.2±2.2 5.3 
SB-T-12854 2.5±0.6 3.5±0.9 1.4 
SB-T-121303 5.7±1.6 4.8±0.9 0.8 
 
aIC50 values (nM) are the mean ± SEM of three independent assays. 
bThe relative resistance values were calculated dividing the IC50 of the βIII transfected 
cell line (wild-type βIII) by the IC50 of the parental HeLa cell line. 
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Table III. Cytotoxicity of SB-T taxanes on the growth of ovarian carcinoma cell lines 
sensitive (1A9) and resistant to paclitaxel (Ptx10 and Ptx22) and to epothilone B (A8) 
by tubulin mutationsa. 
Compound 1A9 PTX10 R/Sb PTX22 R/S A8 R/S 
Taxol 3.9±1.3 81.4±5.4 20.8 32.8±1.9 8.4 4.2±0.7 1.1 
Chitax-4 2.3±0.6 11.6±3.7 5 1.9±0.4 0.83 2±0.04 0.9 
Chitax-40 3.1±0.7 2.4±0.5 0.4 12±1.41 1.9 3.8±0.6 1.2 
SB-T-1102 2.4±1.4 1.75±0.9 0.7 4.95±0.35 2 11.5±1 4.7 
SB-T-1214 5±1.7 10.8±1.4 2.2 7.9±2.3 1.6 12.2±0.5 2.4 
SB-T-12854 3.2±0.4 5.25±0.05 1.6 7 2.2 4±0.8 1.2 
SB-T-
121303 
3.3±1.15 2.9±0.76 0.9 4.9±0.8 1.5 4±0.2 1.2 
aIC50 values of the ligands were determined in parental ovarian carcinoma cells 1A9 and 
the tubulin mutant cell lines bIC50 values (nM) are the mean ± SEM of three 
independent assays . 
bThe relative resistance of the cell line was obtained by dividing the IC50 of the resistant 
cell line by that of the parental 1A9 cell line. 
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Table IV- Free concentration of tubulin required for microtubule assembly in the 
presence and absence of the drugs (Critical concentration) 
 Critical concentration (µM) of 
tubulin in PEDTA4  
DMSO (vehicle) > 200 
Paclitaxel 4.2±0.2a 
Docetaxel 2.4±0.3c 
Chitax-4 2.9±0.4c 
Chitax-40 3.6±1.1c 
SB-T-1102 1.6±0.5 
SB-T-1214 0.9±0.2 
SB-T-12854 0.3±0.1 
SB-T-121303 0.6±0.1 
aData from 56 
bData from 54 
cData from 10 
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Table V: Equilibrium constants of binding of compounds to the paclitaxel site in 
microtubules (x107 M-1) 
Compound 26ºC 27ºC 30ºC 32ºC 35ºC 37ºC 40ºC 42ºC 
Paclitaxela 2.64±0.17 2.19±0.05 1.83±0.09 1.81±0.21 1.43±0.17 1.07±0.11 0.96±0.14 0.94±0.23 
Docetaxela 6.95±0.42 6.57±0.52 5.42±0.42 4.89±0.38 3.93±0.27 3.09±0.22 2.89±0.17 2.38±0.11 
Chitax-4 124±39b ND 85±11 ND 87±19b ND 52±27b ND 
Chitax-40b 612±228b ND 748±152 ND 628±15b ND 355±56b ND 
SB-T-1102 3.0±0.4 2.8±0.5 2.7±0.4 2.7±0.4 2.4±0.3 2.3±0.5 2.7± 0.5 2.5±0.4 
SB-T-1214 12±2 11±1 10±3 9±3 8±2 7±1 7±2 6±1 
SB-T-12854 15±3 14±5 13±4 13±3 10±3 10±1 10±2 8±2 
SB-T-121303 731±82 ND 545±70 ND 478±47 ND 318±83 ND 
aData from 56 
bData from 10 
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Table VI: Thermodynamic parameters of binding of taxanes to its site. 
Compound ∆G 35ºC (kJ/mol) ∆H (kJ/mol) ∆S (kJ/mol K-1) 
Paclitaxela -42.1±0.3 -51±4 -29±13 
Docetaxela -44.8±0.2 -53±2 -26±8 
Chitax-4b -52.7±0.5 -46±13 19±44 
Chitax-40b -57.7±0.1 -26±24 99±80 
SB-T-1102 -43.5±0.3 -8±3 115±11 
SB-T-1214 -46.6±0.6 -32±2 47±6 
SB-T-12854 -47.1±0.7 -28±3 64±10 
SB-T-121303 -57.0±0.2 -31±2 87±7 
aData from56 
bData from10 
 
Table VII. Structural data of the ligand induced microtubules. 
Compound J01 (nm-1) Mean helical 
radius (nm) 
Average pf number 
Paclitaxela 0.0518±0.0004 11.8±0.1 13.0±0.1 
Docetaxela 0.0480±0.0005 12.7±0.2 14.0±0.2 
Chitax-4a 0.0443±0.0008 13.8±0.3 15.2±0.3 
Chitax-40a 0.0521±0.0005 11.7±0.2 12.9±0.2 
SB-T-1102 0.0497±0.0005 12.3±0.2 13.6±0.2 
SB-T-1214 0.0507±0.0004 12.0±0.1 13.2±0.1 
SB-T-12854 0.0493±0.0007 12.4±0.3 13.7±0.3 
SB-T-121303 0.0486±0.0003 12.6±0.2 13.9±0.2 
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Figure Legends 
 
Figure 1. Chemical structures of the compounds employed in this study. 
 
Figure 2. Effect of the SB-T taxanes on the cytoplasmic MTs and DNA morphology of 
A549 cells. Cells were incubated with either drug vehicle (DMSO) or serial 
concentrations of the different drugs. A549 cells were incubated for 24 h with either 
DMSO (A,B); 50 nM (C,D), 100 nM (E,F) or 500 nM (G,H) of paclitaxel; 60 nM (I,J) 
or 120 nM (K,L) of SB-T-1102; 60 nM (M,N) or 120 nM (O,P) of SB-T-1214; 60 nM 
(Q,R) or 120 nM (S,T) of SB-T-12854; 60 nM (U,V) or 120 nM (W,X) of SB-T-
121303. Microtubules are stained with α-tubulin antibodies (A, C, E, G, I, K, M, O, Q, 
S, U, W), whereas DNA (B, D, F, H, J, L, N, P, R, T, V, X) was stained with Hoechst 
33342. The scale bar represents 10 µm. 
Lower panel: Effect of the SB-T taxanes on the cell cycle of A2780, A2780AD and 
A549 cells. Cells were incubated for 20 h with either drug vehicle (DMSO) (control 
cells) or with serial concentrations of each drug. The concentrations shown are those at 
which the maximal accumulation of cells in the G2/M phase was observed. PI denotes 
propidium iodide. 
 
Figure 3. (A) TR-NOESY spectrum of SB-T-12854 in the presence of microtubules. 
(B) STD spectrum of SB-T-12854 in the presence of microtubules. 
 
Figure 4. (A) Comparison between experimental and calculated STD data 
(CORCEMA-ST) of SB-T-12854 bound to microtubules in the pore site: Experimental 
STD (solid line and circles); calculated STD (dashed line and squares). Solutions found 
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for the docking of the luminal site bound form of paclitaxel (B); SB-T-1102 (C); SB-T-
1214 (D); SB-T-12854 (E); SB-T-121303 (F).  
 
Figure 5. SAXS profiles of the ligand-induced microtubules. Paclitaxel (black line), 
docetaxel (red line), SB-T-1102 (green line), SB-T-1214 (blue line), SB-T-12854 
(brown line), SB-T-121303 (pink line). 
 
Figure 6. Model of paclitaxel bound to the binding site in βI (light blue) or βIII (brown) 
tubulin. The colored surfaces represent the calculated volume of the binding site. 
 
Figure 7. Effect of the F272V mutation and the modifications in the C13 side chain of 
the SB-T taxanes on the occupied volume in the paclitaxel binding site. (Sticks) β272 
residue; (grey) surface paclitaxel binding site volume, (blue surface) taxane-occupied 
volume. (A, B) Paclitaxel; (C,D) SB-T-1214; (E-F) SB-T-12854; (G-H) SB-T-121303.  
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